 Mathew Angelos
Concepts (93)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hematopoiesis | 4 | 2024 | 183 | 1.630 |
Why?
| | Pluripotent Stem Cells | 3 | 2018 | 77 | 1.200 |
Why?
| | Receptors, Aryl Hydrocarbon | 2 | 2018 | 51 | 1.120 |
Why?
| | Cell Differentiation | 4 | 2024 | 1902 | 0.800 |
Why?
| | Immunotherapy, Adoptive | 5 | 2025 | 295 | 0.770 |
Why?
| | Hematologic Neoplasms | 1 | 2023 | 140 | 0.750 |
Why?
| | Hematopoietic Stem Cells | 4 | 2024 | 381 | 0.740 |
Why?
| | Neoplasms | 6 | 2025 | 2470 | 0.670 |
Why?
| | Immunotherapy | 3 | 2025 | 592 | 0.500 |
Why?
| | Regenerative Medicine | 1 | 2015 | 46 | 0.490 |
Why?
| | Induced Pluripotent Stem Cells | 1 | 2015 | 221 | 0.410 |
Why?
| | T-Lymphocytes | 3 | 2025 | 1928 | 0.380 |
Why?
| | Fetal Blood | 2 | 2010 | 316 | 0.370 |
Why?
| | Cell Proliferation | 2 | 2018 | 2391 | 0.360 |
Why?
| | Receptors, Antigen, T-Cell | 2 | 2023 | 704 | 0.320 |
Why?
| | Stress, Mechanical | 1 | 2010 | 467 | 0.300 |
Why?
| | Biomarkers, Tumor | 2 | 2025 | 1181 | 0.300 |
Why?
| | Endothelial Cells | 2 | 2010 | 749 | 0.290 |
Why?
| | Embryonic Stem Cells | 2 | 2017 | 118 | 0.260 |
Why?
| | Stem Cells | 1 | 2010 | 577 | 0.260 |
Why?
| | Tumor Microenvironment | 3 | 2025 | 634 | 0.250 |
Why?
| | Medical Oncology | 2 | 2025 | 272 | 0.250 |
Why?
| | Enhancer of Zeste Homolog 2 Protein | 1 | 2025 | 41 | 0.240 |
Why?
| | CD5 Antigens | 1 | 2024 | 9 | 0.230 |
Why?
| | Receptors, Tumor Necrosis Factor, Member 14 | 1 | 2024 | 6 | 0.230 |
Why?
| | Hemangiosarcoma | 1 | 2024 | 20 | 0.220 |
Why?
| | Polycomb Repressive Complex 2 | 1 | 2025 | 63 | 0.220 |
Why?
| | Pyridones | 1 | 2025 | 159 | 0.210 |
Why?
| | Lymphoma, Non-Hodgkin | 1 | 2023 | 77 | 0.210 |
Why?
| | Receptors, Immunologic | 1 | 2024 | 216 | 0.200 |
Why?
| | Receptor, ErbB-2 | 1 | 2025 | 326 | 0.200 |
Why?
| | Cells, Cultured | 3 | 2017 | 4083 | 0.180 |
Why?
| | Hemangioblasts | 1 | 2017 | 4 | 0.150 |
Why?
| | Humans | 16 | 2025 | 129650 | 0.140 |
Why?
| | Antigens, Surface | 1 | 2017 | 151 | 0.140 |
Why?
| | Macrophages | 1 | 2025 | 1480 | 0.140 |
Why?
| | Lymphocyte Subsets | 1 | 2017 | 84 | 0.140 |
Why?
| | Human Embryonic Stem Cells | 1 | 2015 | 23 | 0.120 |
Why?
| | Stem Cell Transplantation | 1 | 2015 | 166 | 0.110 |
Why?
| | Flow Cytometry | 1 | 2017 | 1156 | 0.110 |
Why?
| | Genetic Therapy | 1 | 2015 | 292 | 0.110 |
Why?
| | Animals | 6 | 2025 | 35361 | 0.110 |
Why?
| | Computational Biology | 1 | 2017 | 599 | 0.100 |
Why?
| | Osteoarthritis, Knee | 1 | 2016 | 240 | 0.100 |
Why?
| | Cell Line, Tumor | 3 | 2025 | 3215 | 0.100 |
Why?
| | Breast Neoplasms | 1 | 2025 | 2142 | 0.100 |
Why?
| | Precision Medicine | 2 | 2025 | 387 | 0.090 |
Why?
| | Receptors, Vitronectin | 1 | 2010 | 9 | 0.090 |
Why?
| | Clinical Trials as Topic | 1 | 2015 | 1004 | 0.090 |
Why?
| | Cell Size | 1 | 2010 | 89 | 0.090 |
Why?
| | Diffusion | 1 | 2010 | 117 | 0.090 |
Why?
| | Solutions | 1 | 2010 | 151 | 0.090 |
Why?
| | Fibronectins | 1 | 2010 | 123 | 0.080 |
Why?
| | Cell Count | 1 | 2010 | 314 | 0.080 |
Why?
| | Biological Transport | 1 | 2010 | 401 | 0.080 |
Why?
| | Cell Adhesion | 1 | 2010 | 452 | 0.080 |
Why?
| | Ligands | 1 | 2010 | 622 | 0.080 |
Why?
| | Mechanotransduction, Cellular | 1 | 2009 | 111 | 0.070 |
Why?
| | Mice | 4 | 2025 | 16937 | 0.070 |
Why?
| | United States | 1 | 2023 | 13903 | 0.070 |
Why?
| | Liquid Biopsy | 1 | 2025 | 9 | 0.060 |
Why?
| | Tissue Engineering | 1 | 2009 | 396 | 0.060 |
Why?
| | Biphenyl Compounds | 1 | 2025 | 60 | 0.060 |
Why?
| | Morpholines | 1 | 2025 | 122 | 0.060 |
Why?
| | Benzamides | 1 | 2025 | 207 | 0.060 |
Why?
| | CRISPR-Cas Systems | 1 | 2024 | 109 | 0.050 |
Why?
| | Dogs | 1 | 2024 | 381 | 0.050 |
Why?
| | Antigens, CD19 | 1 | 2023 | 115 | 0.050 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2025 | 814 | 0.050 |
Why?
| | Antibodies | 1 | 2023 | 398 | 0.050 |
Why?
| | Epitopes | 1 | 2023 | 470 | 0.050 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 2024 | 375 | 0.050 |
Why?
| | Proteomics | 1 | 2025 | 1062 | 0.040 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2023 | 964 | 0.040 |
Why?
| | Mice, Knockout | 1 | 2024 | 2871 | 0.030 |
Why?
| | Viscosupplements | 1 | 2016 | 11 | 0.030 |
Why?
| | Injections, Intra-Articular | 1 | 2016 | 46 | 0.030 |
Why?
| | Braces | 1 | 2016 | 21 | 0.030 |
Why?
| | Platelet-Rich Plasma | 1 | 2016 | 32 | 0.030 |
Why?
| | Mesenchymal Stem Cell Transplantation | 1 | 2016 | 50 | 0.030 |
Why?
| | Hyaluronic Acid | 1 | 2016 | 214 | 0.030 |
Why?
| | Female | 3 | 2025 | 68776 | 0.030 |
Why?
| | Adrenal Cortex Hormones | 1 | 2016 | 522 | 0.020 |
Why?
| | Anti-Inflammatory Agents | 1 | 2016 | 480 | 0.020 |
Why?
| | Arthroplasty, Replacement, Knee | 1 | 2016 | 305 | 0.020 |
Why?
| | Signal Transduction | 1 | 2024 | 4925 | 0.020 |
Why?
| | Pain | 1 | 2016 | 789 | 0.020 |
Why?
| | Shear Strength | 1 | 2009 | 67 | 0.020 |
Why?
| | Cell Culture Techniques | 1 | 2009 | 345 | 0.020 |
Why?
| | Aged | 1 | 2025 | 22103 | 0.020 |
Why?
| | Middle Aged | 1 | 2025 | 31154 | 0.010 |
Why?
| | Adult | 1 | 2025 | 35576 | 0.010 |
Why?
| | Male | 1 | 2025 | 63681 | 0.010 |
Why?
|
|
Angelos's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|